Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02828345

Enrollment

Registered

2016-07-11

Start date

2013-11-30

Completion date

2013-12-31

Last updated

2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

This research trial studies the levels of a type of biomarker, circulating tumor cells (CTCs), in the blood of patients with stage I-IV melanoma. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Studying samples of blood in the laboratory obtained before and after treatment from patients with melanoma may help doctors learn more about changes that occur in CTC levels and whether they may predict how well patients will respond to therapy.

Interventions

OTHERSpecimen Collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects must have signed tissue collection consent as described in protocol IRB# 703001,UPCC# 08607, PI: Giorgos Karakousis, MD * Subjects must be competent to consent for themselves. * Subjectsmust be adult (18 years or older). * Subjects must be initiating a new therapy for melanoma (so a pretreatment CTC count can be obtained).

Exclusion criteria

* Children (less than 18yrs) * Patients in whom a pre-treatment CTC level cannot be obtained.

Design outcomes

Primary

Measure	Time frame
Number of changes in CTC level from pre- to post-treatment	two years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026